| CAS ID: | 155213-67-5 |
| Molecular Formula: | C37H48N6O5S2 |
| Molecular Weight: | 721 g/mol |
| Monoisotopic Mass: | 720.3128 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | A-84538 | NORVIR | RITONAVIR | ABBOTT-84538 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1 | See All |
| InChI Key: | NCDNCNXCDXHOMX-XGKFQTDJSA-N | |
| Smiles: | CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc3cncs3)Cc4ccccc4 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT01231685 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 1, 2010 | Last Verified | September 21, 2016 |
| Sponsor | McGill University Health Center | ||
Trial Record 2
| ClinicalTrial ID | NCT00023218 | Disease | Liver fibrosis |
| Phase | Not Applicable | Status | Withdrawn |
| First Received | August 31, 2001 | Last Verified | March 9, 2015 |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) | ||
Trial Record 3
| ClinicalTrial ID | NCT01614405 | Disease | Liver fibrosis |
| Phase | Not Applicable | Status | Completed |
| First Received | June 7, 2012 | Last Verified | December 2, 2015 |
| Sponsor | University of Alberta | ||
Trial Record 4
| ClinicalTrial ID | NCT02442284 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 13, 2015 | Last Verified | October 16, 2017 |
| Sponsor | AbbVie | ||
Trial Record 5
| ClinicalTrial ID | NCT02806362 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Withdrawn |
| First Received | June 20, 2016 | Last Verified | December 5, 2016 |
| Sponsor | AbbVie | ||
Trial Record 6
| ClinicalTrial ID | NCT02265237 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 15, 2014 | Last Verified | August 31, 2017 |
| Sponsor | AbbVie | ||
Trial Record 7
| ClinicalTrial ID | NCT02219477 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 19, 2014 | Last Verified | July 11, 2017 |
| Sponsor | AbbVie | ||
Trial Record 8
| ClinicalTrial ID | NCT02207088 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 1, 2014 | Last Verified | November 9, 2017 |
| Sponsor | AbbVie | ||
Trial Record 9
| ClinicalTrial ID | NCT02219503 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 19, 2014 | Last Verified | June 29, 2016 |
| Sponsor | AbbVie | ||
Trial Record 10
| ClinicalTrial ID | NCT00661349 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Terminated |
| First Received | April 18, 2008 | Last Verified | April 23, 2009 |
| Sponsor | Germans Trias i Pujol Hospital | ||
Trial Record 11
| ClinicalTrial ID | NCT01908660 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | July 26, 2013 | Last Verified | November 11, 2015 |
| Sponsor | Valme University Hospital | ||
Trial Record 12
| ClinicalTrial ID | NCT03053180 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | February 15, 2017 | Last Verified | March 14, 2019 |
| Sponsor | AbbVie | ||
Trial Record 13
| ClinicalTrial ID | NCT02640547 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | December 29, 2015 | Last Verified | October 17, 2018 |
| Sponsor | AbbVie | ||
Trial Record 14
| ClinicalTrial ID | NCT02636608 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | December 22, 2015 | Last Verified | May 30, 2018 |
| Sponsor | AbbVie | ||
Trial Record 15
| ClinicalTrial ID | NCT02615145 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | November 26, 2015 | Last Verified | April 12, 2018 |
| Sponsor | AbbVie | ||